Drug Company CEOs Under Pressure

Main Category: Pharma Industry / Biotech Industry
Also Included In: Health Insurance / Medical Insurance
Article Date: 04 Feb 2010 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:1 and a half stars

1.5 (2 votes)

Healthcare Prof:5 stars

5 (1 votes)

News outlets feature profiles and opinions of the CEOs of some of the largest American drug manufacturers.

Dow Jones Newswires/The Wall Street Journal on Severin Schwan, chief executive of Swiss pharmaceutical company Roche Holding AG: "'It is difficult to gauge the impact of the planned U.S. healthcare reform on the pharmaceutical industry,' Schwan told reporters at a media conference to detail 2009 earnings. 'On the one hand, more U.S. citizens will be getting access to healthcare, which is positive. At the same time, pressure on drug prices will certainly increase,' he added." The wire service adds that he also said "decisions on generic biosimilars will be key" (Greil, 2/3).

The Seattle Times on GlaxoSmithKline PLC CEO Andrew Witty: "[He] has been remaking the company from a pure pharmaceutical business to a diverse healthcare conglomerate, a strategy most rivals now are pursuing. ... Like rivals, it is losing sales to generic competition and reducing staff in Western countries. Witty is pushing to sell more products in fast-growing 'emerging markets' such as Brazil, Russia, India and China. But Witty also is increasing efforts to bring medicines for tropical diseases to the poorest countries, at minimum profit" (Johnson, 2/2).

In a separate article, Dow Jones Newswires/The Wall Street Journal reports on a high and "generational" turnover among pharmaceutical CEOs. "The new leaders are taking over an industry under pressure. The past decade has brought heightened scrutiny of drug safety, government probes of sales and marketing practices, and greater pricing pressure from drug-benefit plans and generic competitors. Drug makers feel compelled to control costs and do more to get results from the billions of dollars they pour into their research labs" (Loftus, 2/2).

This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org.

© Henry J. Kaiser Family Foundation. All rights reserved.



Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Drug Company CEOs Under Pressure." Medical News Today. MediLexicon, Intl., 4 Feb. 2010. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/178158.php>

APA
Kaiser. (2010, February 4). "Drug Company CEOs Under Pressure." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/178158.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »